Valuation: Ionis Pharmaceuticals, Inc.

Market Cap 9.51B 8.21B 7.7B 7.02B 13.19B 910B 13.38B 90.31B 35.39B 456B 35.71B 34.94B 1,516B P/E 2026 *
-16x
P/E 2027 * -30.7x
Enterprise Value 9.41B 8.12B 7.62B 6.94B 13.05B 900B 13.23B 89.34B 35.01B 451B 35.33B 34.56B 1,499B EV / Sales 2026 *
10.2x
EV / Sales 2027 * 6.84x
Free-Float
99.09%
Yield 2026 *
-
Yield 2027 * -
1 day+1.75%
1 week+2.18%
Current month+12.38%
1 month+6.97%
3 months-19.77%
6 months-28.49%
Current year-26.46%
1 week 54.91
Extreme 54.91
58.38
1 month 50
Extreme 50.005
58.38
Current year 50
Extreme 50.005
86.74
1 year 41.7
Extreme 41.705
86.74
3 years 23.95
Extreme 23.95
86.74
5 years 23.95
Extreme 23.95
86.74
10 years 23.95
Extreme 23.95
86.74
Manager TitleAgeSince
Investor Relations Contact 60 01/07/2012
Chief Executive Officer 64 01/01/2020
Director of Finance/CFO 64 01/05/2000
Director TitleAgeSince
Director/Board Member 64 13/12/2005
Director/Board Member 73 01/05/2002
Director/Board Member 64 25/03/2019
Date Insider Type Main position Quantity % Market Cap.
7/31/26 A Buy

Director

5,000 0.0030%
7/15/26 A Free

Director

3,399 0.0021%
7/15/26 A Free

Director

3,399 0.0021%
Change 5-day change 1-year change 3-year change Capi.($)
+1.75%+2.18%+33.96%+48.68% 9.51B
+0.68%-2.28%+1.91%+19.70% 48.42B
+5.63%+4.06%+490.60%+634.98% 43.66B
+4.09%+0.38%+12.85%+87.41% 39.51B
+2.00%-0.65%+24.87%+12.24% 38.95B
-0.50%+0.85%+20.60%+58.18% 32.61B
-0.24%-2.71% - - 16.32B
+2.48%-1.59%+28.08%+133.79% 16.15B
-0.62%-0.06%+3.95%+27.74% 14.16B
+1.88%+3.39%+82.44%+43.29% 13.37B
Average +1.72%-0.19%+77.70%+118.45% 27.27B
Weighted average by Cap. +2.09%-0.56%+99.85%+148.64%

Financials

2026 *2027 *
Net sales 921M 795M 746M 679M 1.28B 88.04B 1.29B 8.74B 3.43B 44.11B 3.46B 3.38B 147B 1.4B 1.21B 1.13B 1.03B 1.94B 134B 1.97B 13.28B 5.21B 67.03B 5.25B 5.14B 223B
Net income -590M -509M -478M -435M -818M -56.4B -830M -5.6B -2.19B -28.26B -2.21B -2.17B -94B -322M -278M -261M -237M -446M -30.76B -452M -3.05B -1.2B -15.41B -1.21B -1.18B -51.26B
Net Debt -103M -88.89M -83.39M -75.95M -143M -9.84B -145M -978M -383M -4.93B -387M -378M -16.41B 57.45M 49.6M 46.53M 42.38M 79.69M 5.49B 80.8M 545M 214M 2.75B 216M 211M 9.15B
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,480
Date Price Change Volume
17/08/26 $58.18 +1.64% 935,264
14/08/26 $57.24 +2.45% 1,353,737
13/08/26 $55.87 -1.17% 1,220,460
12/08/26 $56.53 +2.00% 1,999,667
11/08/26 $55.42 -2.67% 2,407,128
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
57.24USD
Average target price
89.33USD
Spread / Average Target
+56.07%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IONS Stock